Francesco Ravera

Dr. Francesco Ravera


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2021 in Cancers
Verified
Journal Article
Open access
PDF file
GCGabriella Cirmena
Gabriella Cirmena
MDMartina Dameri
Martina Dameri
FRFrancesco Ravera
Francesco Ravera
PFPiero Fregatti
Piero Fregatti
ABAlberto Ballestrero
Alberto Ballestrero
GZGabriele Zoppoli
Gabriele Zoppoli
Current approaches for cancer detection and characterization are based on radiological procedures coupled with tissue biopsies, despite relevant limitations in terms of overall accuracy and feasibility, including relevant patients’ discomfort. Liquid biopsies enable the minimally invasive collection and analysis of circulating biomarkers released from cancer cells and stroma, representing therefore a promising candidate for the substitution or integration in the current standard of care. Despite the potential, the current clinical applications of liquid biopsies are limited to a few specific purposes. The lack of standardized procedures for the pre-analytical management of body fluids samples and the detection of circulating biomarkers is one of the main factors impacting the effective advancement in the applicability of liquid biopsies to clinical practice. The aim of this work, besides depicting current methods for samples collection, storage, quality check and biomarker extraction, is to review the current techniques aimed at analyzing one of the main circulating biomarkers assessed through liquid biopsy, namely cell-free nucleic acids, with particular regard to circulating tumor DNA (ctDNA). ctDNA current and potential applications are reviewed as well.

16 July 2025 in The Journal of Liquid Biopsy
Verified
Journal Article
Open access
MSMaria Luisa Schiavone
Maria Luisa Schiavone
RSRosa Scarpitta
Rosa Scarpitta
FRFrancesco Ravera
Francesco Ravera
SBSara Bleve
Sara Bleve
CRCarolina Reduzzi
Carolina Reduzzi
Cristian ScatenaCristian Scatena
Cristian Scatena
Breast cancer (BC) is the most frequent cancer and the leading cause of cancer-related death among women worldwide. It represents a heterogeneous group of diseases with distinct morphological, immunophenotypic, and molecular profiles, which significantly impact clinical behavior and therapeutic response. Moreover, under treatment pressure, tumor cells may undergo molecular changes and phenotypic plasticity, leading to resistance and therapeutic failure. Although tissue biopsy remains the gold standard for diagnosis and molecular characterization, it has several limitations, including invasiveness, sampling bias, and the inability to dynamically capture tumor evolution over time. Hence, a non-invasive and repeatable approach capable of real-time monitoring is increasingly needed.